Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Outlook Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of OTLK: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders6762−5
Shares8.38M4.55M−3.83M (−45.7%)
Value$44.8M$8.60M−$36.2M (−80.8%)

New holders (14)

Institutions that held Outlook Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to OTLK in Q4 2024
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC130,374$246.4K0.00%
Gsa Capital Partners LLP100,319$190.0K0.01%
Susquehanna International Group, LLP81,275$153.6K0.00%
AQR Capital Management LLC59,320$112.1K0.00%
Commonwealth Equity Services, LLC25,615$48.0K0.00%
Qube Research & Technologies Ltd13,510$25.5K0.00%
JustInvest LLC11,951$22.6K0.00%
Two Sigma Investments, LP10,591$20.0K0.00%
Fifth Third Wealth Advisors LLC10,000$18.9K0.00%
Citadel Advisors LLC8,692$16.4K0.00%
Riggs Asset Managment Co. Inc.2,500$4.65K0.00%
SBI Securities Co., Ltd.210$3970.00%
EverSource Wealth Advisors, LLC188$3550.00%
IFP Advisors, Inc3$60.00%

Sold out (19)

Institutions that held Outlook Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.